Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with AdvancedA Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid Tumors (REFMAL 449) Solid Tumors (REFMAL 449)
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.